<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151422">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02001389</url>
  </required_header>
  <id_info>
    <org_study_id>EVP-6308-002</org_study_id>
    <nct_id>NCT02001389</nct_id>
  </id_info>
  <brief_title>Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308</brief_title>
  <official_title>A Phase 1, Open-Label, Multiple Ascending Dose, [18F]MNI-659 PET-Imaging Study to Evaluate PDE10A Occupancy After Dosing With EVP-6308 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FORUM Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FORUM Pharmaceuticals Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose-
      and concentration-dependent displacement of [18F]MNI-659 [a PET tracer targeting
      phosphodiesterase 10 (PDE10)] by EVP-6308.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Target occupancy of [18F]MNI-659.</measure>
    <time_frame>Baseline and Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in binding potential.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of EVP-6308 as assessed by adverse events, vital signs, clinical laboratory tests, C-SSRS, and electrocardiogram (ECG).</measure>
    <time_frame>Baseline to Day 4 or Early Termination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The following will be evaluated: clinical laboratory evaluations (chemistry, hematology, coagulation and urinalysis), physical examination, directed neurological examination, vital signs, orthostatic blood pressure, 12-lead ECG, and assessment for suicidality.  Adverse events and concomitant medications will be collected from the time of signing the informed consent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of EVP-6308 and EVP-6308 N-oxide.</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameters to be determined include Cmax, Tmax, t1/2, and CL/F.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>EVP-6308; Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose, Capsule, Twice Daily, Day 1 through Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP-6308; Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP-6308; Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high intermediate dose, Capsule, Once Daily, Day 1 through Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP-6308; Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose, Capsule, Once Daily, Day 1 through Day 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVP-6308</intervention_name>
    <description>Arms 1, 2, 3, 4</description>
    <arm_group_label>EVP-6308; Arm 1</arm_group_label>
    <arm_group_label>EVP-6308; Arm 2</arm_group_label>
    <arm_group_label>EVP-6308; Arm 3</arm_group_label>
    <arm_group_label>EVP-6308; Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Healthy male or female volunteers, 18 to 50 years of age

        Exclusion Criteria:

          -  Clinically significant abnormalities on physical examination, medical history,  ECG ,
             vital signs, laboratory values, or unstable medical or psychiatric illness

          -  Any disorder that may interfere with drug absorption.

          -  Clinically significant allergy or sensitivity to medications Positive test for human
             immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C
             antibody.

          -  Pregnant or breast feeding.

          -  History of exposure to any radiation &gt;15 mSv/year (e.g., occupational or radiation
             therapy) over the past year.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nathan Buerstatte</last_name>
    <phone>617-374-5784</phone>
    <email>nbuerstatte@forumpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enzyme occupancy</keyword>
  <keyword>Positron emission tomography (PET)</keyword>
  <keyword>Phosphodiesterase 10 inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
